FDA To Assess Anemia Drug Risks In Kidney Patients
A U.S. Food and Drug Administration advisory panel will meet on Monday to evaluate chronic kidney disease patients' use of popular anemia drugs made by Johnson & Johnson and Amgen Inc....To view the full article, register now.
Already a subscriber? Click here to view full article